Phase II Study of Pasireotide LAR in Patients With Metastatic Neuroendocrine Carcinomas
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2018
At a glance
- Drugs Pasireotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 18 Jun 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 18 Jun 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 09 Jan 2018 Planned End Date changed from 1 Jul 2018 to 1 Dec 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History